企業プロフィール
Xilio Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- XLO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
9.49 USD (+3.49%)
終値
最終更新: 2026年8月17日
53.9M USD
時価総額
株価変動の要因
As of Aug 17, 2026, XLO closed up 3.49% at $9.49. No new same-company headline was identified in the current news window.
企業概要
Tumor-Activated Immunotherapy
Xilio Therapeutics engineers cytokines, antibodies, and T-cell engagers that remain masked until activated within the tumor microenvironment.
XTX501
XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors.
Masked T-Cell Engagers
Earlier programs include XTX601 targeting CLDN18.2 and a multispecific engager targeting PSMA and STEAP1.
今後のカタリスト
- An IND submission for XTX501 is planned around mid-2026.
- A Phase 1 study of XTX501 is expected to begin in the second half of 2026.
- Initial Phase 1 data in metastatic non-small cell lung cancer are expected in the second half of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。